The Pap test, introduced by George Papanicolaou, is a cytological screening examination that detects abnormal epithelial cells scraped from transformation zone of uterine cervix.[@b1-asm-4-245] Use of the technique in cervical cancer screening reduces the incidence and mortality of cervical cancer in developed countries.[@b2-asm-4-245],[@b3-asm-4-245] However, women with equivocal cytological results usually undergo repeat Pap smears to obtain a definite diagnosis, which may cause anxiety. Immunocytochemistry for p16 protein has been shown as an effective approach for triage in women with cytological abnormalities, such as atypical squamous cells of undetermined significance (ASCUS).[@b4-asm-4-245] The p16 protein, a cyclin dependent kinase inhibitor, decelerates the cell cycle by facilitating the re-binding of retinoblastoma protein (Rb) and E2F transcription factor. The E7 oncoprotein, which is the product of E7 oncogene of hr-HPV interrupts the linkage between Rb and E2F transcription factor, resulting in disruption of Rb/E2F pathway.[@b4-asm-4-245] Therefore, overexpression of p16 protein in a dysplastic cervical epithelial cell is indicative of hr-HPV induced transformation.[@b5-asm-4-245] The Ki-67 antigen is a nuclear protein that expresses during all phases of the cell cycle except G0. Under normal physiological conditions, its expression is limited in basal layer squamous epithelium of uterine cervix. A staining protocol that simultaneously detects p16 protein and Ki-67 antigen in the same cervical epithelial cell has been established.[@b6-asm-4-245] Co-expression of p16 protein (tumor suppressor marker) and Ki-67 antigen (proliferative marker) in the same cervical epithelial cell indicates deregulation of the cell cycle and is supposed to be a positive test result.[@b6-asm-4-245] The hr-HPV testing has also been proposed as a tool for triage of equivocal or low-grade cytological abnormalities as its role in cervical cancer screening evolves.[@b7-asm-4-245],[@b8-asm-4-245] A systematic review and meta-analysis showed that p16 immunocytochemistry has higher specificity than hr-HPV testing to detect underlying high-grade squamous intraepithelial lesions (HSIL) in triage of ASUCS or low-grade squamous intraepithelial lesions (LSIL).[@b9-asm-4-245] Estimates of p16/Ki-67 dual stain in triage of abnormal Pap smear differ from study to study. The aim of the review was to evaluate the accuracy of p16/Ki-67 dual stain for triage of women with abnormal Pap smear results.

PATIENTS AND METHODS
====================

We followed the review protocol based on the guideline for systematic review of diagnostic accuracy studies and used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement as framework for reporting the review.[@b10-asm-4-245],[@b11-asm-4-245]

Literature search
-----------------

We searched PubMed, The Cochrane Library, BioMed Central, and ClinicalTrials.gov using Boolean logic of the following search terms: patients (cervical intraepithelial neoplasia OR CIN OR cervical dysplasia OR HSIL OR LSIL OR squamous intraepithelial lesion OR precancer), intervention (cytology OR pap smear OR pap test) (p16 or p16 protein or Ki-67 or Ki-67 protein or immunocytochemistry or p16/Ki-67 dual stain), and outcome (sensitivity OR diagnostic accuracy). The search strategy in PubMed is in the [Appendix](#app1-asm-4-245){ref-type="app"}. No publication date restriction was applied. English language studies were reviewed. The last search was performed on October 4, 2014.

Study selection and quality assessment
--------------------------------------

We included studies that addressed the test performance of p16/Ki-67 immunocytochemistry and hr-HPV testing, as a comparator, for triage of women with cytological abnormalities. We also included primary studies focused on p16/Ki-67 dual stain performed on conventional smear or liquid-based cytology. Either prospective trials or retrospective studies were included. We excluded review articles and research that reported insufficient data for calculating sensitivity and specificity. One reviewer initially screened titles and abstracts for potentially relevant studies. Two reviewers independently examined full-text articles to determine eligibility. Disagreements were resolved by discussion. We assessed the methodological quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2).[@b12-asm-4-245] The QUADAS-2 consists of four domains: patient selection, index test, reference standard, and flow and timing. Each domain has "signaling questions" that help in judging the bias and applicability of studies. A study is considered to be high quality if it used consecutive recruitment of participants, all participants used the same reference standard, index test interpretation was done without knowledge of the reference standard, and all recruited participants were included in analyses.

Data extraction and synthesis
-----------------------------

We extracted data from each study to construct a 2×2 table of true positives, true negatives, false positives, and false negatives to calculate sensitivity and specificity of both the p16/Ki-67 dual stain and hr-HPV testing. Sensitivity is the proportion of true positive results out of all who have the target condition (illness) whereas specificity is the proportion of true negative results out of all who do not have the target condition (illness). Diagnostic odds ratio (DOR) was calculated as sensitivity/(1- sensitivity) over (1- specificity)/specificity. [@b13-asm-4-245] A diagnostic test is thought to be discriminative if it has a DOR greater than one.[@b14-asm-4-245] We defined p16/Ki-67 immunocytochemistry performed on abnormal Pap smear as the index test. We considered molecular testing for hr-HPV as the comparator. A biopsy sample taken from uterine cervix was regard as the reference standard.

We conducted a meta-analysis of p16/Ki-67 results extracted from included studies to generate pooled sensitivity, specificity, and DOR using a random-effects model. We plotted the summary receiver operating characteristic (SROC) curve to demonstrate overall test performance of p16/Ki-67 dual stain. The closer the curve approaches the upper left-handed corner, the better overall diagnostic performance of the test.[@b15-asm-4-245] We also carried out a meta-analysis for hr-HPV assays using a random-effects model to produce summary sensitivity and specificity. Pooled estimates including sensitivity, specificity, and DOR were generated along with associated 95% confidence interval (95% CI). Owing to inconsistent study design and cytological preparation, we investigated heterogeneity across studies. I^2^ is one of the indicators of quantitative evaluation of heterogeneity. The I^2^ expresses the percentage of the total variation across studies due to true differences rather than chance. Values of 25%, 50%, and 75% represent low, moderate, and high level of heterogeneity, respectively. [@b16-asm-4-245] All analyses were performed by using MetaDiSc 1.4 software package.[@b17-asm-4-245]

RESULTS
=======

Overall accuracy of p16/Ki-67 dual stain and hr- HPV assay
----------------------------------------------------------

Seven eligible studies[@b18-asm-4-245]--[@b24-asm-4-245] comprising 2628 participants were identified ([Figure 1](#f1-asm-4-245){ref-type="fig"}). Five studies were carried out with prospective study design ([Table 1](#t1-asm-4-245){ref-type="table"}).[@b18-asm-4-245]--[@b22-asm-4-245] [Table 2](#t2-asm-4-245){ref-type="table"} summarizes the test results for each study. In the two retrospective studies, one retrieved Pap smears from their departmental files and the other used the residual specimens collected from the authors' previous research.[@b23-asm-4-245],[@b24-asm-4-245] One study used conventional smears and the other used liquid-based cytology. Schmidt et al reported two sets of estimates based on triages of ASCUS and LSIL.[@b24-asm-4-245] To avoid double counting of results from the same participants, we extracted data for the LSIL triage. The summary sensitivity and specificity of p16/Ki-67 dual stain for triage of abnormal Pap smear results were 0.91 (95% CI, 0.89 to 0.93) and 0.64 (95% CI, 0.62 to 0.66), respectively ([Figure 2](#f2-asm-4-245){ref-type="fig"}, [Figure 3](#f3-asm-4-245){ref-type="fig"}). The meta-analysis for p16/Ki-67 dual stain yielded a pooled DOR of 15.35 (95% CI, 8.2 to 28.74) ([Figure 4](#f4-asm-4-245){ref-type="fig"}), showing the discriminatory power of the dual stain. We obtained pooled hr-HPV test estimates that had sensitivity of 0.94 (95%CI, 0.92 to 0.96) and specificity of 0.35 (95% CI, 0.32 to 0.37). The area under the curve (AUC) of an SROC plot presents the overall accuracy of a diagnostic test. A perfect test shows an AUC equal to 1. The AUC of an excellent test should be in the region of 0.97 or above. An AUC ranging from 0.93 to 0.96 is very good; an AUC of 0.75 to 0.92 is good.[@b25-asm-4-245] The SROC curve ([Figure 5](#f5-asm-4-245){ref-type="fig"}) of p16/Ki-67 showed an AUC of 0.87, indicating that the overall test performance of p16/Ki-67 was good. The Youden index is defined as (sensitivity + specificity -- 1).[@b26-asm-4-245] A good diagnostic test has a Youden index over 0.5. The Youden index of p16/Ki-67 dual stain was 0.55. The meta-analysis, which was conducted using a random-effects model, demonstrated that p16/Ki-67 dual stain had comparable sensitivity and higher specificity, compared with hr-HPV testing.

Investigation of heterogeneity
------------------------------

The I^2^ index (45.3%) of the meta-analysis in sensitivity is lower than that (90.4%) in specificity. The Cochran's Q test for the pooled DOR yielded a result of 20.34 (*P*=.0024), indicating that there was heterogeneity across studies. We performed a subgroup analysis to investigate heterogeneity. Study design might have an impact on accuracy of p16/Ki-67 dual stain. The prospectively conducted studies had a pooled sensitivity and specificity of 0.90 (95%CI, 0.87 to 0.93) and 0.69 (95% CI, 0.67 to 0.72), respectively. The pooled sensitivity and specificity of the index tests in studies using liquid-based cytology were 0.91 (95%CI, 0.89 to 0.93) and 0.64 (95%CI, 0.61 to 0.66). The results were nearly identical to these of all included studies. Two studies which addressed the triage of atypical squamous cells could not exclude high-grade squamous intraepithelial lesion (ASC-H) for cervical intraepithelial neoplasia 2 or worse (CIN2+) and had slightly decreased sensitivity of 0.88 (95%CI, 0.76 to 0.95) and specificity of 0.60 (95%CI, 0.54 to 0.67).[@b19-asm-4-245],[@b21-asm-4-245]

DISCUSSION
==========

Our study showed high sensitivity and moderate specificity for the p16/Ki-67 dual stain for triage of abnormal Pap smears. The presence of illness could be ruled out if a diagnostic test that has high sensitivity for the condition yields a negative result. The meta-analysis generated the pooled estimates, indicating that the p16/Ki- 67 dual stain was superior to hr-HPV testing. Arbyn et al performed a meta-analysis that showed that two types of hr-HPV assays were less specific in detecting CIN 2+ in women with ASCUS or LSIL, compared with our study.[@b27-asm-4-245] According to consensus guidelines developed by the American Society for Colposcopy and Cervical Pathology, hr-HPV testing is the management of choice in women with either ASCUS or LSIL.[@b28-asm-4-245] We suggested that the p16/Ki-67 dual stain might be an alternative procedure in the management of patients with abnormal cervical cytology. Laboratory professionals could conduct a p16/Ki-67 dual stain by using the residual specimen after liquid-based cytology preparation. The potential benefit of the p16/Ki-67 dual stain for women with an abnormal Pap test is the reduction in repeat cytology which is a worrisome problem. Colposcopy is one way of managing women with LSIL cytology.[@b28-asm-4-245] Negative p16/Ki-67 immunocytochemistry performed on an abnormal or equivocal Pap smear, which could be free of HSIL, might lead to decreased colposcopic referral, easing the gynecologists' workload. Fujii et al stated that p16/Ki-67 immunocytochemistry was a more accurate triage test for identifying CIN2+ in LSIL or ASCUS specimen, compared with hr-HPV testing.[@b29-asm-4-245] Their finding was compatible with our study outcome. The majority of HPV infections in young women are transient.[@b30-asm-4-245] About 90% of women with new HPV infections resolve within two years.[@b30-asm-4-245] A retrospective study of 680 biopsy-proven LSIL patients demonstrated that 49 percent regressed to negative at six months.[@b31-asm-4-245] Such phenomenon might lead to lower specificity of hr-HPV testing in triage of LSIL. Therefore, we prefer p16/Ki-67 dual stain to hr-HPV testing.

No study had a case-control study design and four studies reported consecutive enrollment of participants. [@b18-asm-4-245],[@b19-asm-4-245],[@b22-asm-4-245],[@b24-asm-4-245] Three studies reported that p16/Ki-67 dual stain was interpreted without knowledge of the result of pathological examination.[@b18-asm-4-245],[@b22-asm-4-245],[@b23-asm-4-245] One study recorded that the biopsy result was interpreted without knowledge of p16/Ki-67 dual stain.[@b18-asm-4-245] Three studies reported that they analyzed all participants.[@b21-asm-4-245]--[@b23-asm-4-245] There were no concerns about patient selection, index test, or reference standards. Regarding applicability, the studies had a low risk of bias. Four studies had a high risk of bias owing to incomplete patient analyses ([Table 3](#t3-asm-4-245){ref-type="table"}).[@b18-asm-4-245]--[@b20-asm-4-245],[@b24-asm-4-245] The specificity estimates of the included studies ranged from 0.51 to 0.72. The meta-analysis of the p16/Ki-67 dual stain in specificity generated an I2 of 90.4%, indicating that study design, patient spectrum, triage, and specimen type across studies appeared to have greater impact on pooled specificity than on pooled sensitivity.

The strength of evidence of our study relied on a rigorous methodological quality assessment based on QUADAS-2. Regarding applicability, patient selection, index test, and the reference standards of studies had a low risk of bias. Two reviewers independently reviewed titles, abstracts, and full-texts. A meta-epidemiologic analysis has indicated that MEDLINE alone is sufficient for systematic reviews of diagnostic accuracy.[@b32-asm-4-245]

A limitation of our study is that no studies in the meta-analysis examined the accuracy of the p16/Ki-67 dual stain for interpretation of glandular neoplasms. Six studies did not report whether the reference standard results were interpreted without knowledge of the index tests.[@b19-asm-4-245]--[@b24-asm-4-245] Four studies stated that not all patients were included in the analyses.[@b18-asm-4-245]--[@b20-asm-4-245],[@b24-asm-4-245] Lijmer et al reported that studies using case-control study design might produce three-fold overestimation of diagnostic accuracy effect, compared with studies with clinical cohort.[@b33-asm-4-245] No study in this review used a case-control study design.

In summary, our investigation yielded robust summary estimates of the p16/Ki-67 dual stain, indicating that it could be an accurate triage test to identify HSIL in abnormal Pap smear cytology. Further high quality studies using consecutive patient enrollment and complete participant analysis are required to improve understanding of the applicability of p16/Ki-67 dual stain in triage of women with abnormal Pap smear results. Future systematic reviews on the diagnostic accuracy of the p16/Ki-67 dual stain for triage of endocervical glandular abnormalities detected on Pap smears are also needed to explore the overall performance of the technique.
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  Key words                            Search details
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  cervical intraepithelial neoplasia   "cervical intraepithelial neoplasia"\[MeSH Terms\] OR ("cervical"\[All Fields\] AND "intraepithelial"\[All Fields\] AND "neoplasia"\[All Fields\]) OR "cervical intraepithelial neoplasia"\[All Fields\]
  CIN                                  "Comput Nurs"\[Journal\] OR "cin"\[All Fields\] OR "Comput Intell Neurosci"\[Journal\] OR "cin"\[All Fields\] OR "Comput Inform Nurs"\[Journal\] OR "cin"\[All Fields\]
  cervical dysplasia                   "uterine cervical dysplasia"\[MeSH Terms\] OR ("uterine"\[All Fields\] AND "cervical"\[All Fields\] AND "dysplasia"\[All Fields\]) OR "uterine cervical dysplasia"\[All Fields\] OR ("cervical"\[All Fields\] AND "dysplasia"\[All Fields\]) OR "cervical dysplasia"\[All Fields\] OR "cervical intraepithelial neoplasia"\[MeSH Terms\] OR ("cervical"\[All Fields\] AND "intraepithelial"\[All Fields\] AND "neoplasia"\[All Fields\]) OR "cervical intraepithelial neoplasia"\[All Fields\] OR ("cervical"\[All Fields\] AND "dysplasia"\[All Fields\])
  cytology                             "cytology"\[Subheading\] OR "cytology"\[All Fields\] OR "cytological techniques"\[MeSH Terms\] OR ("cytological"\[All Fields\] AND "techniques"\[All Fields\]) OR "cytological techniques"\[All Fields\] OR "cytology"\[All Fields\] OR "cell biology"\[MeSH Terms\] OR ("cell"\[All Fields\] AND "biology"\[All Fields\]) OR "cell biology"\[All Fields\]
  pap smear                            "papanicolaou test"\[MeSH Terms\] OR ("papanicolaou"\[All Fields\] AND "test"\[All Fields\]) OR "papanicolaou test"\[All Fields\] OR ("pap"\[All Fields\] AND "smear"\[All Fields\]) OR "pap smear"\[All Fields\]
  pap test                             "papanicolaou test"\[MeSH Terms\] OR ("papanicolaou"\[All Fields\] AND "test"\[All Fields\]) OR "papanicolaou test"\[All Fields\] OR ("pap"\[All Fields\] AND "test"\[All Fields\]) OR "pap test"\[All Fields\]
  sensitivity                          "sensitivity and specificity"\[MeSH Terms\] OR ("sensitivity"\[All Fields\] AND "specificity"\[All Fields\]) OR "sensitivity and specificity"\[All Fields\] OR "sensitivity"\[All Fields\]
  diagnostic                           "diagnosis"\[MeSH Terms\] OR "diagnosis"\[All Fields\] OR "diagnostic"\[All Fields\]
  p16 protein                          "cyclin-dependent kinase inhibitor p16"\[MeSH Terms\] OR ("cyclin-dependent"\[All Fields\] AND "kinase"\[All Fields\] AND "inhibitor"\[All Fields\] AND "p16"\[All Fields\]) OR "cyclin-dependent kinase inhibitor p16"\[All Fields\] OR ("p16"\[All Fields\] AND "protein"\[All Fields\]) OR "p16 protein"\[All Fields\]
  protein                              "proteins"\[MeSH Terms\] OR "proteins"\[All Fields\] OR "protein"\[All Fields\]
  immunocytochemistry                  "immunohistochemistry"\[MeSH Terms\] OR "immunohistochemistry"\[All Fields\] OR "immunocytochemistry"\[All Fields\]
  stain                                "staining and labeling"\[MeSH Terms\] OR ("staining"\[All Fields\] AND "labeling"\[All Fields\]) OR "staining and labeling"\[All Fields\] OR "stain"\[All Fields\]
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###### 

Characteristics of the seven included studies.

  Study                                    Study design                 No. of participant (total/data extraction)   Mean age (range)      Triage                     Specimen type        Index test    Comparator         Detection     Reference standard
  ---------------------------------------- ---------------------------- -------------------------------------------- --------------------- -------------------------- -------------------- ------------- ------------------ ------------- --------------------------------
  Ordi et al[@b18-asm-4-245]               Prospective, consecutive     1169/1123                                    35.8 (18--91)         abnormal Pap test          ThinPrep             CINtec PLUS   Hybrid Capture 2   CIN2+         Biopsy, endocervical curettage
  Killeen et al[@b19-asm-4-245]            Prospective, consecutive     515/232                                      35.8 (21--86)         ASCUS, LSIL, ASC-H, HSIL   ThinPrep             CINtec PLUS   Cervista           CIN2/3        Biopsy
  Vrdoljak-Mozetic et al[@b20-asm-4-245]   Prospective                  155/145                                      34.9 (19--69)         CIN1                       Conventional smear   CINtec PLUS   Hybrid Capture 2   CIN2+         Biopsy
  Byun et al[@b21-asm-4-245]               Prospective                  56/56                                        46 (25--83)           ASC-H, LSIL-H              SurePath             CINtec PLUS   Cytoactive         CIN2+         Histology
  Waldstroem et al[@b22-asm-4-245]         Consecutive                  469/469                                      32.3 (16--25)         LSIL                       ThinPrep             CINtec PLUS   APTIMA             CIN2+/CIN3+   Histology
  Loghavi et al[@b23-asm-4-245]            Retrospective                188/188                                      median: 30 (15--77)   ASCUS, LSIL                SurePath             CINtec PLUS   Cervista           CIN2+         Histology
  Schmidt et al[@b24-asm-4-245]            Retrospective, consecutive   810/415                                      \>18                  LSIL                       ThinPrep             CINtec PLUS   Hybrid Capture 2   CIN2+/CIN3    Biopsy

ASCUS= atypical squamous cells of undetermined significance; ASC-H= atypical squamous cells cannot exclude high grade squamous intraepithelial lesion; CIN= cervical intraepithelial neoplasia; CIN 2+ = cervical intraepithelial neoplasia 2 or worse; CIN 3+ = cervical intraepithelial neoplasia 3 or worse; HSIL= high-grade squamous intraepithelial lesion; LSIL= low-grade squamous intraepithelial lesion; LSIL-H= low-grade squamous intraepithelial lesion cannot exclude high grade squamous intraepithelial lesion. Manufacturers are as follows (listed in alphabetical order by product): APTIMA, Gen-Probe company; Cervista, Hologic; CINtec PLUS, Roche; Cytoactive, Cytoimmun Diagnostics GmbH; Hybrid Capture 2, QIAGEN; SurePath, Becton, Dickinson and Company; ThinPrep, Hologic

###### 

Summary of test results for each study in the meta-analysis.

  Study                                    True positive   False positive   False negative   True negative   Total
  ---------------------------------------- --------------- ---------------- ---------------- --------------- -------
  Ordi et al[@b18-asm-4-245]               360             203              36               524             1123
  Killeen et al[@b19-asm-4-245]            33              75               2                122             232
  Vrdoljak-Mozetic et al[@b20-asm-4-245]   16              36               4                89              145
  Byun et al[@b21-asm-4-245]               16              17               5                18              56
  Waldstroem et al[@b22-asm-4-245]         77              186              10               196             469
  Loghavi et al[@b23-asm-4-245]            30              74               1                83              188
  Schmidt et al[@b24-asm-4-245]            129             89               8                189             415

###### 

Quality of the seven studies included in the meta-analysis.

  Study                                    Risk of bias   Applicability concerns                       
  ---------------------------------------- -------------- ------------------------ ---- ---- ---- ---- ----
  Ordi et al[@b18-asm-4-245]               LR             LR                       LR   HR   LR   LR   LR
  Killeen et al[@b19-asm-4-245]            LR             UR                       UR   HR   LR   LR   LR
  Vrdoljak-Mozetič et al[@b20-asm-4-245]   UR             UR                       UR   HR   LR   LR   LR
  Byun et al[@b21-asm-4-245]               UR             UR                       UR   UR   LR   LR   LR
  Waldstroem et al[@b22-asm-4-245]         LR             LR                       UR   LR   LR   LR   LR
  Loghavi et al[@b23-asm-4-245]            UR             LR                       UR   LR   LR   LR   LR
  Schmidt et al[@b24-asm-4-245]            LR             UR                       UR   HR   LR   LR   LR

HR=high risk; LR=low risk; UR=unknown risk
